Silexion Therapeutics Corp released a letter to shareholders from Chairman and CEO, Ilan Hadar, highlighting the significant achievements in 2025 and outlining milestones for 2026.
The company's lead asset, SIL204, demonstrated significant tumor inhibition in preclinical studies across pancreatic, colorectal, and lung cancer models.
Silexion aims to address the $30+ billion global KRAS-driven cancer market with its Pan-KRAS therapeutic platform.
Transformational Year in 2025
Positioned SIL204 for human clinical trials, progressing towards breakthrough treatments for aggressive cancers.
KRAS Mutation Challenges
KRAS mutations are among the most challenging targets in oncology, with limited treatment options; Silexion's RNAi-based approach aims to target KRAS at the genetic level.
Market Potential
The broader market for Silexion's solution may exceed $30 billion annually, focusing on pancreatic, colorectal, and lung cancer treatment.
- Silexion achieved significant scientific progress in 2025, demonstrating SIL204's potency and applicability across multiple cancer types and KRAS mutations.
- Preclinical results showed over 90% inhibition of cancer cell growth, validating activity against eight distinct KRAS mutations.
- Operational milestones include completing toxicology studies with no organ toxicity and receiving positive feedback on trial design from regulatory authorities.
Silexion Therapeutics is on track to make a significant impact in the oncology landscape by addressing the challenges posed by KRAS-driven cancers with its innovative approach and promising lead asset, SIL204.